Development of novel anti-cancer immune therapies targeting CD147 antigen

Research Project

Project/Area Number	15K10590
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Research Field	Urology
Research Institution	Okayama University
Principal Investigator	Kobayashi Yasuyuki 岡山大学, 大学病院, 講師 (50366027)
Co-Investigator(Kenkyū-buntansha)	黄鵬岡山大学, 医歯薬学総合研究科, 助教 (00610841) 渡部昌実岡山大学, 大学病院, 教授 (70444677) 植木英雄岡山大学, 医学部, 技術専門職員 (90537218)
Project Period (FY)	2015-04-01 – 2018-03-31
Project Status	Completed (Fiscal Year 2017)
Budget Amount *help	¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000) Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000) Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000) Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Keywords	癌治療 / ＣＤ147 / 腫瘍学 / CD147 / 液性免疫 / Emmprin / 抗体
Outline of Final Research Achievements	In this study, we validated and confirmed the anti-cancer immune activity of the fusion proteins consisted of CD147 antigen and cytokines, in in vivo experimental models. We also disclosed the inhibitory function of REIC/Dkk-3 protein overexpressed by Ad-REIC agents, in the endogenous CD147 expression in bladder and prostate cancer cells. We believe that the CD147 antigen could be a promising target for anti-cancer therapy. We are going to conduct the further study to develop novel anti-cancer immune therapies targeting CD147 antigen.